Brief Results
In Adults with chronic kidney disease (eGFR ≥25 ml min-1 1.73 m-2 and UACR ≥30 and <3,500 mg g-1) and overweight or obesity (BMI ≥27 kg m-2) without diabetes, Semaglutide 2.4 mg per week for 24 weeks compared to Placebo for 24 weeks showed Semaglutide treatment reduced UACR by -52.1% (95% CI -65.5, -33.4; p < 0.0001) compared to placebo.
Study Details
|
Population Adults with chronic kidney disease (eGFR ≥25 ml min-1 1.73 m-2 and UACR ≥30 and <3,500 mg g-1) and overweight or obesity (BMI ≥27 kg m-2) without diabetes |
|
Intervention Semaglutide 2.4 mg per week for 24 weeks |
|
Comparison Placebo for 24 weeks |
|
Outcome Semaglutide treatment reduced UACR by -52.1% (95% CI -65.5, -33.4; p < 0.0001) compared to placebo |
Summary
This randomized double-blind placebo-controlled clinical trial compared semaglutide 2.4 mg per week to placebo in adults with chronic kidney disease and overweight or obesity without diabetes over 24 weeks. The study aimed to assess the percentage change in UACR. Results showed that semaglutide treatment led to a significant reduction in UACR by -52.1% compared to placebo (95% CI -65.5, -33.4; p < 0.0001). Gastrointestinal adverse events were more common with semaglutide. Overall, semaglutide demonstrated a clinically meaningful reduction in albuminuria in this patient population.
Publication Details
Authors: Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, López-Martínez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP, Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL
Journal: Nature medicine
Date: 22 Jan 2025
This PICO summary was generated through the collaborative efforts of Hormone Insight’s artificial intelligence system and underwent expert clinical review to ensure accuracy and relevance.
